Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CarMax, Inc (KMX) vs Philip Morris International Inc. (PM) Price & Performance

CarMax, IncTrade
Philip Morris International Inc.Trade

Price performance (Past 24H)

Key statistics

CarMax, Inc vs Philip Morris International Inc. — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 40.9× CarMax, Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Philip Morris International Inc. for 85 Days on average.

KMXPM
Market Cap
$7.64B$312.50B
Volume
3,610,1165,517,172
Sector
Consumer CyclicalConsumer Staples
52-Week High
$64.22$200.50
52-Week Low
$30.88$144.33
Typical Hold Time
49 Days85 Days
Enterprise Value
$25.34B$355.62B
Dividend Yield
—3.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CarMax, Inc

CarMax (KMX) trades at $52.61, down 1.26% amid bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.37 and net margin of 1.06%, while revenue trends downward from $31.9B in 2022 to $26.4B in 2025. Recent Q2 2026 earnings of $1.16 per share beat expectations by 58%, driven by 19.5% revenue growth and improved unit sales under the 'Shift into GEAR' strategy.

The outlook remains cautious with analyst consensus at Hold (62%) and $58.89 price target suggesting 12% upside. Key risks include declining profit margins, high debt load ($18.14B long-term), and competitive pressures. Positive catalysts include continued execution of turnaround strategy and November 3 strategic update.

Philip Morris International Inc.

Philip Morris International (PM) trades at $200.5, up 4.05% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, and revenue growth is robust, driven by smoke-free products like IQOS and ZYN. The stock is near its pivot point of $200, with support at $197 and resistance at $203. Cash flow trends show improving operational performance, though debt levels remain elevated.

The outlook is positive due to earnings momentum and smoke-free product expansion, but risks include regulatory pressures and high valuation. Wall Street consensus is bullish with a $212.17 price target, suggesting upside potential. Investors should weigh growth prospects against macroeconomic and industry-specific headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KMX

No sentiment data available yet.

PM
1% Buy99% Sell
Avg holding period · 85 Days

Top news

Latest headlines on both assets

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX →

About Philip Morris International Inc.

Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.

Read more on PM →